2024-10-16
September 26, 2024, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") self-developed productProcaterol Hydrochloride Oral Solution (trade name: 贝舒清®) has been successfully approved by the Chinese CDE, and Beimei Pharmaceutical is the MAH of this product.✦•✦✦✦ProcaterolHydrochloric Oral Solution is a respiratory...
More +2024-09-25
Recently, at the "Promoting High Quality Development" series of themed press conferences held by the State Council Information Office, Huang Guo, Deputy Director of the National Medical Products Administration, pointed out that in response to the issue of pediatricdrugs, the NMPAhas issued multiple measures to encourage research and innovation in pediatric drugs, sta...
2024-09-25
Recently, at the "Promoting High Quality Development" series of themed press conferences held by the State Council Information Office, Huang Guo, Deputy Director of the National Medical Products Administration, pointed out that in response to the issue of pediatricdrugs, the NMPAhas issued multiple measures to encourage research and innovation in pediatric drugs, sta...
2024-09-14
September 14, 2024, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") self-developed product Procaterol Hydrochloride Inhalation Solution (trade name:倍舒捷®)has been successfully approved by the Chinese CDE, and Beimei Pharmaceutical is the MAH of this product.Procaterol Hydrochloride Inhalation Solution is mainly u...
2024-09-14
September 14, 2024, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") self-developed product Procaterol Hydrochloride Inhalation Solution (trade name:倍舒捷®)has been successfully approved by the Chinese CDE, and Beimei Pharmaceutical is the MAH of this product.Procaterol Hydrochloride Inhalation Solution is mainly u...
2024-05-16
Shenzhen Beimei Pharmaceutical Co., Ltd. ("Beimei Pharma") announced that on May 15th, 2024, an asset purchase agreement (the "Agreement") was signed with Sol-Gel Technologies, Ltd. ("Sol-Gel", Nasdaq stock Code: SLGL) to acquire all relevant assets of dermatology product TWYNEO® in the mainland of China, Hong Kong, Macau, Taiwan and I...
2024-05-16
Shenzhen Beimei Pharmaceutical Co., Ltd. ("Beimei Pharma") announced that on May 15th, 2024, an asset purchase agreement (the "Agreement") was signed with Sol-Gel Technologies, Ltd. ("Sol-Gel", Nasdaq stock Code: SLGL) to acquire all relevant assets of dermatology product TWYNEO® in the mainland of China, Hong Kong, Macau, Taiwan and I...
2023-08-31
On August 31, 2023, Dr. B.Partha Saradhi Reddy, Chairman of Hetero Labs Limited,Mr. Bheemireddy Murali Krishnar Reddy, President of Emerging Markets,Mr. Variyath Muraleedharan, VP of International Markets,Mr. Suman Reddy Bandi, Head of API,and Tanya Wang, BD of Formulation， together visited Shenzhen Beimei Pharmaceutical Co., Ltd. Ms. Wu Guangmei, C...
2023-08-31
On August 31, 2023, Dr. B.Partha Saradhi Reddy, Chairman of Hetero Labs Limited,Mr. Bheemireddy Murali Krishnar Reddy, President of Emerging Markets,Mr. Variyath Muraleedharan, VP of International Markets,Mr. Suman Reddy Bandi, Head of API,and Tanya Wang, BD of Formulation， together visited Shenzhen Beimei Pharmaceutical Co., Ltd. Ms. Wu Guangmei, C...
2023-08-16
Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has completed a newfinancinground with investors including Jiangsu Jinqiao Private Equity Fund Management Co., Ltd., Nanshan SEIInvestment and Jiangsu Aosaikang Pharmaceutical Co., Ltd. This fund raisedwill be used to continue to promote the commercialization of seve...
2023-08-16
Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has completed a newfinancinground with investors including Jiangsu Jinqiao Private Equity Fund Management Co., Ltd., Nanshan SEIInvestment and Jiangsu Aosaikang Pharmaceutical Co., Ltd. This fund raisedwill be used to continue to promote the commercialization of seve...
2023-08-03
August 2, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd. (hereinafter referred to as "BeimeiPharmaceuticals") in collaboration with Hetero Labs Limited is pleased to announce that ourimported drug formulation "Lacosamide Oral Solution (Trade Name: 乐美定®)" has successfully received approval from the NMPA, the National Medical Products Administration,for...
2023-08-03
August 2, 2023, Shenzhen BeimeiPharmaceutical Co., Ltd. (hereinafter referred to as "BeimeiPharmaceuticals") in collaboration with Hetero Labs Limited is pleased to announce that ourimported drug formulation "Lacosamide Oral Solution (Trade Name: 乐美定®)" has successfully received approval from the NMPA, the National Medical Products Administration,for...
2023-07-27
On July 27, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") first self-developed product "atomoxetine hydrochloride oral solution (trade name: 贝择思®)” has been successfully approved by the Chinese CDE for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years...
2023-07-27
On July 27, 2023, Shenzhen Beimei Pharmaceutical Co., LTD. (hereinafter referred to as "Beimei Pharmaceutical") first self-developed product "atomoxetine hydrochloride oral solution (trade name: 贝择思®)” has been successfully approved by the Chinese CDE for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adolescents aged 6 years...
2023-07-10
Recently, the three-day CPHI&PMEC China 2023were held atthe Shanghai New International Expo Center. Hetero Labs Limited, the premiumpartner of Shenzhen Beimei Pharmaceutical Co., Ltd.,participated inthe exhibition and awarded Beimei Pharmaceutical The Most Valuable PartnerCollaboration Award.(BeiMei Pharma's Chairman and CEO, Claire Wu, receives the ...
2023-07-10
Recently, the three-day CPHI&PMEC China 2023were held atthe Shanghai New International Expo Center. Hetero Labs Limited, the premiumpartner of Shenzhen Beimei Pharmaceutical Co., Ltd.,participated inthe exhibition and awarded Beimei Pharmaceutical The Most Valuable PartnerCollaboration Award.(BeiMei Pharma's Chairman and CEO, Claire Wu, receives the ...
2023-06-27
June 25, 2023, the production base of Beimei Pharma (a wholly-owned subsidiary of Beimei Pharmaceutical—Jiangsu Beimei Pharmaceutical Co., Ltd.) successfully settled in the International Pharmaceutical Innovation Industrial Park of Lianyungang Free Trade Zone. The attendees inthe ceremony were: JiajiongZhang, Deputy Mayor of Lianyungang City,YuanYin, Deputy Director ...
2023-06-27
June 25, 2023, the production base of Beimei Pharma (a wholly-owned subsidiary of Beimei Pharmaceutical—Jiangsu Beimei Pharmaceutical Co., Ltd.) successfully settled in the International Pharmaceutical Innovation Industrial Park of Lianyungang Free Trade Zone. The attendees inthe ceremony were: JiajiongZhang, Deputy Mayor of Lianyungang City,YuanYin, Deputy Director ...
